Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. - sprookjes - yvandenbroek - TriplyDB

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

http://www.wikidata.org/entity/Q33601338

about

18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease Clinical trial methodologies for disease-modifying therapeutic approaches The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception 18F-florbetaben Aβ imaging in mild cognitive impairment Cyberinfrastructure for Open Science at the Montreal Neurological Institute Structural Neuroimaging Genetics Interactions in Alzheimer's Disease Imago Mundi, Imago AD, Imago ADNI The clinical value of large neuroimaging data sets in Alzheimer's disease PyXNAT: XNAT in Python COINS: An Innovative Informatics and Neuroimaging Tool Suite Built for Large Heterogeneous Datasets The Alzheimer's disease neuroimaging initiative: progress report and future plans A comprehensive genetic association study of Alzheimer disease in African Americans.Genome-wide association analysis of age-at-onset in Alzheimer's disease Genome-wide association study of Alzheimer's disease Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging.The mismatch negativity as an index of cognitive decline for the early detection of Alzheimer's disease Do brain image databanks support understanding of normal ageing brain structure? A systematic review.Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort.MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study.Necessity of normative data on the Japanese version of the Wechsler Memory Scale-Revised Logical Memory subtest for old-old people.Multiscale adaptive generalized estimating equations for longitudinal neuroimaging data Mapping the effect of the apolipoprotein E genotype on 4-year atrophy rates in an Alzheimer disease-related brain network Attempted and successful compensation in preclinical and early manifest neurodegeneration - a review of task FMRI studies 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data.Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging.Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry.Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease.Biomarkers in translational research of Alzheimer's disease Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.

P2860

Q24186399-6FF73383-8F4F-45CC-ABC5-B80CC195D263 Q24197654-C3D9175C-F119-4712-95CB-D4D0B380F5A6 Q26801629-90A7AF57-CBCB-435F-99EC-1DECD72ADBE1 Q26801640-CE516873-62C4-48E3-A875-680CEB2233F3 Q26801657-B52C434E-7FB9-4E62-A971-76EA13751D13 Q26823454-24E96295-F661-4B2E-B981-AC2D85829477 Q26996741-73467587-E8B3-4613-8667-A9307DFA9091 Q27001770-35FB23A1-5F16-4D0E-B1FD-F2B7E1AF10AC Q27006831-4E0A99F4-7133-48F1-904A-B38AA82B60BF Q27499311-EA921532-4CD9-463F-AD21-7AA4C08ABF70 Q28555091-20B748C9-215E-40F0-B41E-C7E8190F589A Q28601824-5BE825C1-8E69-481D-B625-546377D380CE Q28650395-B6461587-627F-4955-8CE6-7A5EA8867BC9 Q28709465-FCE117DE-7FFE-46EB-98D1-AEF38EE17790 Q28729910-E83835F4-78BE-45AD-9CA8-813460C3B1F0 Q28740512-077A8B2F-8984-4585-AF69-1B1270018DE7 Q28749585-4A49C732-66E1-40B2-A97F-BD90619AC8C8 Q29417006-660ADD2D-3F74-46A7-87EA-E56897F64136 Q29417033-BE6271AD-FAE4-4079-B7D5-47417A356B59 Q29417071-6815F59D-7CD1-4677-AFB3-B2775DF9AC70 Q29417147-85AA46C6-5C58-41DE-A603-4A22DD67D562 Q29614879-82857227-DAEB-4CE8-9ECC-D890D4BE24A3 Q30354417-C458B602-515C-4C88-A995-E88F472F0C89 Q30374343-AF025227-805D-430F-A350-361CF0793390 Q30485331-411205DD-A06D-4EFD-B08D-2CD92DAC5FFB Q30499904-A0BF3AF5-E2CF-4C85-914F-3FA85F07D303 Q30540746-AD60E690-7F8F-47D9-8030-787E7FD9A570 Q30583805-2076665F-AD27-49FD-9C21-A8FA23600D34 Q30586512-67633AB9-688D-475B-846E-1931926F9040 Q30744917-1DA0DF5F-612E-4468-83FC-548F71AECD54 Q30862037-68B4F3CA-D672-4E2F-9AD2-27220DFAD2C2 Q30971403-0D7F39FE-3567-41BE-B0DF-2E686EB6E85A Q31097104-FBA157D3-8070-431E-AE72-BD6320ABDA17 Q31110973-0E0C26C8-C3F2-4D54-BD3C-54FDF4BF611F Q31121286-779F7720-8AC3-4A86-9D25-9977F51F8A4D Q31147608-E38254B8-F236-42D5-8FE4-AA1760FB2755 Q31158600-AA940AF8-BFC9-4FD3-B56E-B20605BC0151 Q33540910-BB49B3F5-48E6-4F52-872D-8FA525134619 Q33556189-9CCFF800-C0D2-4C53-AF11-7AB386060EDB Q33559175-1369EECB-FC0C-4C39-99B2-0F83D7BD7200

P2860

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

http://www.wikidata.org/entity/Q33601338

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

@ast

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

@en

type

label

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

@ast

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

@en

prefLabel

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

@ast

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

@en

P1433

Q33601338-CADB6B1B-996E-498A-909C-C883C13435A0

P1476

Q33601338-EC24B05D-270F-4E8D-8F7B-06A910A4A858

P2093

Q33601338-046CAAA3-DB55-4C20-B238-CB8C3D2A9B98

Q33601338-380650EA-3063-4EAA-B68E-5643F332CE79

Q33601338-42A7B8C9-7891-4B00-B8D2-648DEF456720

Q33601338-4874380C-39FF-4035-915F-2FC06A5C9160

Q33601338-501ED211-6B48-44B4-86FA-1F571332D26F

Q33601338-70413E90-550A-400C-9BFF-B7FF46058B49

Q33601338-B37356D4-B17E-4A54-89B7-ED3BEDB2371A

Q33601338-B6FEDB9B-41A9-4767-A0F6-3D51CC9A8DC0

Q33601338-C0225E4A-F6AD-4EB1-A622-97B40829510B

Q33601338-D92EC399-08E3-4A10-8432-6ABC2069DFC6

P2860

Q33601338-0F51AE33-9D0A-4214-BC94-92A7F4FB8DA0

Q33601338-1035AAD2-8C65-41CB-AB5D-FD91C1ABB948

Q33601338-12FEE8CE-ABE8-438E-A008-CA78DCA67B0A

Q33601338-130E85D2-6A79-4BD5-B628-BCE96CCFFF3B

Q33601338-2C44E148-AD6F-4FAB-8CC0-939EF19DC729

Q33601338-70E47DF8-2770-4942-A6DF-3F373D68188C

Q33601338-7C2F2C14-D6C1-4E4E-9700-9F46B42AAD25

Q33601338-7F33C89C-5220-467C-8CCB-917E61590E29

Q33601338-910F854F-75CD-4F69-8214-680E80B9A949

Q33601338-973CAFAB-9F5B-4B7D-B2F7-780FAAA762C0

P304

Q33601338-14200614-914B-4D95-BE29-1DD8E922393C

P31

Q33601338-AF5E1A5A-5F66-4EE7-B471-D4C6A19413B3

P356

Q33601338-E978CAF6-A258-40CF-A7CD-D51D443B0651

P407

Q33601338-E4DAC521-12B7-46AA-9397-47EF1D69D688

P433

Q33601338-4DD0D1D3-C9D9-46C7-95CB-26000C13AECA

P478

Q33601338-BAD7D364-2BA4-4CE7-9C29-4F68803C26E9

P50

Q33601338-8A0D852F-0E15-4BA4-833E-B97EA6393A6D

Q33601338-B41D61BC-AA7D-497E-B86A-65A7C343F7A2

P577

Q33601338-0437E289-C123-4830-B565-A8F6C073C55E

P698

Q33601338-D2595E25-B9A8-4498-8332-1F97C26286AA

P921

Q33601338-064B502F-66D6-490B-A135-8B50703DA8AD

Q33601338-C4BE3CE7-4139-498E-A942-D942ABF41084

Q33601338-F82EA5B6-4014-4F02-A937-638D58D16F9B

P932

Q33601338-BCE206CB-5B1C-456D-BD9F-010A5BD88A71

P356

WNL.0B013E3181CB3E25

P1433

P1476

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

@en

P2093

A C Gamst

http://www.w3.org/2001/XMLSchema#string

C R Jack

http://www.w3.org/2001/XMLSchema#string

D J Harvey

http://www.w3.org/2001/XMLSchema#string

J Q Trojanowski

http://www.w3.org/2001/XMLSchema#string

L A Beckett

http://www.w3.org/2001/XMLSchema#string

L M Shaw

http://www.w3.org/2001/XMLSchema#string

M W Weiner

http://www.w3.org/2001/XMLSchema#string

P S Aisen

http://www.w3.org/2001/XMLSchema#string

R C Petersen

http://www.w3.org/2001/XMLSchema#string

W J Jagust

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Mild cognitive impairment: clinical characterization and outcome

Neuropathologic features of amnestic mild cognitive impairment

Random-effects models for longitudinal data

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

Development and validation of a geriatric depression screening scale: a preliminary report

Mild cognitive impairment as a diagnostic entity

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Cerebral blood flow in dementia.

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.

P304

201-209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3181CB3E25

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Michael Donohue

P577

2009-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20042704

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Alzheimer's Disease Neuroimaging Initiative

P932

2809036

http://www.w3.org/2001/XMLSchema#string